Dbv technologies reports full year 2023 financial results and business update

Montrouge, france, march 7, 2024 dbv technologies reports full year 2023 financial results and business update advanced viaskin™ peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old) strengthened executive leadership team in preparation for bla submission reported cash and cash equivalents of $141 million dbv technologies (euronext: dbv – isin: fr0010417345 – nasdaq stock market: dbvt), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023. the audit procedures have been substantially completed by the company's statutory auditors and financials – prepared under both us gaap and ifrs for the purpose of form 10-k and universal registration document respectively – were approved by the board of directors on march 7, 2024.
DBVT Ratings Summary
DBVT Quant Ranking